Weekly Recap: Attruby $1B annual target and BBP-418 FDA review Nov 27, 2026
BridgeBio Pharma, Inc. (NASDAQ:BBIO) projects Attruby to exceed $1B annual revenue ~six quarters after launch, targeting blockbuster status and peak sales >$4B while also advancing BBP-418 for LGMD2I/R9 toward a possible Nov 27, 2026 FDA decision and reporting real-world benefits of acoramidis vs t…